Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.
Related Posts
How Is The Market Feeling About Stryker?
Stryker’s (NYSE:SYK) short percent of float has risen 14.29% since its last report. The company recently reported that it has…
Amid Russia-Ukraine War, Boris Johnson Says Donald Trump ‘Could Be Just What The World Needs’ In Eyebrow-raising Column
Former U.K. prime minister Boris Johnson has publicly endorsed Donald Trump’s return to the White House, suggesting it could be a…
Should you buy Microsoft before today’s earnings announcement?
As Microsoft gears up to reveal its quarterly earnings after the market closes, all eyes are on the tech giant,…